Search alternatives:
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
linear decrease » linear increase (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
linear decrease » linear increase (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
-
2121
The study timeline.
Published 2025“…<div><p>Consumer food waste remains a significant concern in the United States, where approximately 40% of food goes uneaten, leading to major economic and environmental consequences. …”
-
2122
-
2123
-
2124
-
2125
-
2126
a, Anti-correlation of gene expression between <i>dmdR1</i> and its predicted regulon. Left: Pearson correlation coefficients (PCCs) between <i>dmdR1</i> and all genes with a DmdR1 position weight matrix (PWM) score greater than 15 in their regulatory region. The vertical dashed line marks the refined PWM score threshold of 22.875....
Published 2025“…Left: Pearson correlation coefficients (PCCs) between <i>dmdR1</i> and all genes with a DmdR1 position weight matrix (PWM) score greater than 15 in their regulatory region. The vertical dashed line marks the refined PWM score threshold of 22.875. …”
-
2127
Summary of study eligibility criteria.
Published 2025“…Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility.</p><p>Methods</p><p>ACB women aged 18–49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.5mg/day); a vaginal probiotic (RepHresh™ Pro-B™) administered twice daily; a combination of Estring© and vaginal RepHresh™ Pro-B™ (twice daily); or the Estring© and oral RepHresh™ Pro-B™ (twice daily), for a duration of 30 days. …”
-
2128
Summary of study participation and feasibility.
Published 2025“…Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility.</p><p>Methods</p><p>ACB women aged 18–49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.5mg/day); a vaginal probiotic (RepHresh™ Pro-B™) administered twice daily; a combination of Estring© and vaginal RepHresh™ Pro-B™ (twice daily); or the Estring© and oral RepHresh™ Pro-B™ (twice daily), for a duration of 30 days. …”
-
2129
-
2130
-
2131
-
2132
Flow diagram of participants selection.
Published 2025“…Multivariable logistic regression evaluated associations between BRI and LMM, while multivariable linear regression assessed relationships between BRI and appendicular skeletal muscle mass (ASM)/BMI. …”
-
2133
Minimal data set.
Published 2025“…Multivariable logistic regression evaluated associations between BRI and LMM, while multivariable linear regression assessed relationships between BRI and appendicular skeletal muscle mass (ASM)/BMI. …”
-
2134
Weighted comparison of baseline characteristics.
Published 2025“…Multivariable logistic regression evaluated associations between BRI and LMM, while multivariable linear regression assessed relationships between BRI and appendicular skeletal muscle mass (ASM)/BMI. …”
-
2135
-
2136
-
2137
-
2138
-
2139
-
2140